Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA expands approval of breast cancer drug Kisqali
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-posit
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, Novartis said.
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.
Kisqali Approved for HR-Positive, HER2-Negative Early Breast Cancer
The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
The Food and Drug Administration expanded the approval of
Kisqali
, a drug for metastatic
breast
cancer
, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
FDA Approves Kisqali Regimen for HR+/HER2- Early Breast Cancer
Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence.
FDA Expands Use of Breast Cancer Drug Kisqali
The FDA approval of Kisqali for this early breast cancer population, including those with NO [hasn't spread to nearby lymph nodes] disease, is a pivotal moment in improving our approach to care,” said Dr.
NBC New York
4d
FDA expands approval of breast cancer drug Kisqali to earlier stage patients
The Food and Drug Administration expanded the approval of
Kisqali
, a drug for metastatic
breast
cancer
, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday ...
Hosted on MSN
5d
Novartis’ breast cancer trial of Kisqali reveals 28.5% risk reduction
Kisqali is a selective cyclin-dependent kinase inhibitor that targets proteins involved in the rapid division of cancer cells ...
pharmaphorum
3d
Lilly on alert as new Kisqali approval threatens Verzenio
Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Secret Service admits failure
Accepts CNN debate invite
Released after guilty plea
J&J unit files for bankruptcy
Sesame Place suit verdict
Russia threatens retaliation
FBI agents board vessel
$230 million crypto theft
Feds subpoena Schaeffer
TN abortion law blocked
Beirut strike death toll
Rallies in North Carolina
Stein's ballot bid rejected
Disney to stop using Slack
Sues pharmacy middlemen
Bill to boost security OK'd
Hand count approved in GA
In-person voting begins
ISR strike on Gaza school
Baby powder recalled
Top Hezbollah leader killed?
Pandas leaving for China
Drug price challenge revived
WI high court to decide
SC 1st execution in 13 years
144K+ Mavericks recalled
Boeing defense chief exits
House repeals emission rules
FDA approves flu vaccine
1st rabies outbreak in seals
Hiker injured in bear attack
Feedback